Here we report the cellular arachidonate (AA)-releasing function of group IIF secretory phospholipase A 2 (sPLA 2 -IIF), a sPLA 2 enzyme uniquely containing a longer C-terminal extension. sPLA 2 -IIF increased spontaneous and stimulus-dependent release of AA, which was supplied to downstream cyclooxygenases and 5-lipoxygenase for eicosanoid production. sPLA 2 -IIF also enhanced interleukin 1-stimulated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. AA release by sPLA 2 -IIF was facilitated by oxidative modification of cellular membranes. Cellular actions of sPLA 2 -IIF occurred independently of the heparan sulfate proteoglycan glypican, which acts as a functional adaptor for other group II subfamily sPLA 2 s. Confocal microscopy revealed the location of sPLA 2 -IIF on the plasma membrane. The unique C-terminal extension was crucial for its plasma membrane localization and optimal cellular functions. sPLA 2 -IIF expression was increased in various tissues from lipopolysaccharidetreated mice and in ears of mice with experimental atopic dermatitis. In human rheumatoid arthritic joints, sPLA 2 -IIF was detected in synovial lining cells, capillary endothelial cells, and plasma cells. These results suggest that sPLA 2 -IIF is a potent regulator of AA metabolism and participates in the inflammatory process under certain conditions.
Secretory phospholipase A 2 (sPLA 2 )
1 comprises a large family of lipolytic enzyme, in which 10 isozymes (groups IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XII) have been identified in mammals (1, 2) . Group I, II, V, and X sPLA 2 s are closely related in that they have in common a molecular mass of 14 -16 kDa, a conserved active site, Ca 2ϩ -binding site, 6 -8 disulfides, and a conserved three-dimensional structure. Group III and group XII sPLA 2 s each have unique structural characteristics, and display homology to the I/II/V/X sPLA 2 s only in the active site and Ca 2ϩ -binding loop (3, 4) . Group IB (sPLA 2 -IB), or pancreatic sPLA 2 , is abundantly present in pancreatic juice, where it plays a role in digestion of dietary phospholipids, and is also expressed in trace amounts in several nondigestive organs (5) . sPLA 2 -IIA, known as an inflammatory-type sPLA 2 , is detected in a variety of tissues and cells and is highly up-regulated in response to inflammatory stimuli both in vitro and in vivo (6 -11) . Accumulating evidence suggests that sPLA 2 -IIA plays an augmentative role in stimulus-coupled arachidonic acid (AA) release and subsequent cyclooxygenase (COX)-mediated prostaglandin (PG) generation (10 -16) . This enzyme has been also implicated in cell growth and death (17) , atherosclerosis (18) , tumorigenesis (19) , degranulation (20) , anti-coagulation (21) , and defense against bacteria (22) (23) (24) . sPLA 2 -IIC is highly expressed in rodent testes, but only a pseudogene for this enzyme has been found in the human genome (25) . sPLA 2 -IID and -IIE are structurally most related to sPLA 2 -IIA, showing nearly 50% homology to each other (26 -29) . sPLA 2 -IID augments stimulus-induced AA release in a manner similar to sPLA 2 -IIA (16) and its expression is also regulated by proinflammatory stimulus (27) . sPLA 2 -IIF has an unusually long, proline-rich C-terminal extension containing a free cysteine (28, 30) . The AA-releasing function of this enzyme has not yet been investigated. sPLA 2 -V undergoes stimulus-dependent induction in various tissues and immune cells (31) (32) (33) (34) (35) and promotes PG generation often more potently than does sPLA 2 -IIA (12) (13) (14) (15) (16) (32) (33) (34) . The genes for sPLA 2 -IIA, IIC, IID, IIE, IIF, and V sPLA 2 s are clustered at the same chromosome locus (30) , suggesting that they have arisen from a common ancestor by gene duplication. Based on this and the fact that these 6 sPLA 2 s have similar structural features, they are often referred to as the group II subfamily sPLA 2 s. sPLA 2 -X has structural characteristics of both group I and II enzymes (36) and releases cellular AA potently even under the conditions where the cells are resistant to sPLA 2 -IB, -IIA, and -V (15, 16, (37) (38) (39) (40) . The elevated expression of sPLA 2 -X in some colon adenocarcinoma neoplastic cells suggests its possible participation in the COX-2-dependent development of colorectal cancer (40) . sPLA 2 s display very distinct membrane and heparanoid binding properties, which dictate their behaviors in various mammalian cells. The prototypic isozyme, sPLA 2 -IIA, binds very poorly to zwitterionic phosphatidylcholine (PC) and thereby acts poorly on the PC-rich external leaflet of the plasma membrane of resting cells (41, 42) . In activated cells, however, this enzyme is sorted into the caveolin-rich vesicular and perinuclear compartments during its secretion and internalization processes through the association with glypican, a glycosylphosphatidylinositol-anchored form of the heparan sulfate proteoglycan (HSPG). After proper sorting, the enzyme releases AA from the rearranged membrane microdomains that may be rich in anionic or oxidized phospholipids (14 -16, 43-45) . Basic amino acid clusters located over most of the surface of sPLA 2 -IIA are crucial for its association with HSPG and therefore for its cellular AA-releasing function (42, 46) . This pathway, designated as the HSPG-shuttling pathway, is utilized by several other heparin-binding sPLA 2 s, such as sPLA 2 -IID and sPLA 2 -V (12, 13, 16) . Conversely, HSPGs can also exert a negative regulatory effect on these heparin-binding sPLA 2 s by facilitating their internalization and degradation in some instances (47, 48) .
In contrast, sPLA 2 -X, which displays high affinity for PCrich membranes but shows no affinity for heparanoids, can release AA from the PC-rich external surface of the plasma membrane with no dependence on HSPG (15, 16, 37) . This mechanism is called the external plasma membrane pathway. sPLA 2 -V, which shows high affinity toward PC-rich membranes, also utilizes this pathway to release AA according to the type of cell (16, (33) (34) (35) 47) . In addition, the functions of several sPLA 2 s, such as sPLA 2 -IB and -X, can be also modified by the M-type sPLA 2 receptor, which transduces sPLA 2 -mediated cell activation signals (49, 50) or promotes sPLA 2 internalization and degradation (51) .
In the present study, we have examined the regulation of AA release and eicosanoid biosynthesis by sPLA 2 -IIF, the newest member of the group II subfamily of sPLA 2 s. Our results reveal that the modes of action of sPLA 2 -IIF share some features of those of other group II subfamily sPLA 2 s and sPLA 2 -X, but sPLA 2 -IIF displays some novel features. The expression of sPLA 2 -IIF is elevated in various tissues during inflammatory responses in vivo, suggesting that, as has been proposed for other group II subfamily sPLA 2 s, sPLA 2 -IIF may play a role in inflammation.
EXPERIMENTAL PROCEDURES
Materials-Human embryonic kidney (HEK) 293 cells (Human Science Research Resources Bank) and rat basophilic leukemia (RBL)-2H3 cells (Riken Cell Bank) were cultured in RPMI 1640 medium (Nissui Pharmaceutical Co.) containing 10% (v/v) fetal calf serum (FCS; Bioserum) as described previously (12) (13) (14) (15) (16) . The cDNAs for mouse and human sPLA 2 -IIFs (28, 30), human COX-1 and COX-2 (13), human microsomal PGE 2 synthase (mPGES) (52), rat glypican-1 (14) , and porcine 12/15-lipoxygenase (LOX) (43) were described previously. HEK293 cells stably expressing mouse sPLA 2 -IIA, mouse sPLA 2 -IID, human sPLA 2 -V, human sPLA 2 -X, human COX-2, and human mPGES were described previously (13) (14) (15) (16) 52) . BALB/c and C57BL/6 mice were from Nippon Bio-supply Center.
The enzyme immunoassay kits for PGE 2 and LTC 4 and the COX-2 inhibitor NS-398 were purchased from Cayman Chemicals. The rabbit anti-human COX-1 and goat anti-human COX-2 antibodies were purchased from Santa Cruz. A23187 was purchased from CalBiochem. The LOX inhibitor nordihydroguaiaretic acid (NDGA) was from BIOMOL. Human IL-1␤ was purchased from Genzyme. LipofectAMINE PLUS and LipofectAMINE 2000 reagents, Opti-MEM medium, geneticin, and TRIzol reagent were obtained from Invitrogen. Fluorescein isothiocyanate-conjugated anti-mouse IgG and horseradish peroxidase-conjugated anti-goat IgG were purchased from Zymed Laboratories Inc. Mouse monoclonal anti-FLAG antibody, lipopolysaccharide (LPS; Salmonella minnesota Re 595), and heparin were from Sigma. Mouse IgE anti-trinitrophenyl and trinitrophenyl-conjugated bovine serum albumin were provided by Dr. H. Katz (Harvard Medical School). HeparinSepharose was purchased from Amersham Biosciences. Zeocin, hygromycin, and the pCR3.1 and pcDNA3.1 series of vectors containing a neomycin-, zeocin-, or hygromycin-resistant gene were from Invitrogen.
Antisera for sPLA 2 -IIF-Recombinant human sPLA 2 -IIF was produced in Escherichia coli after in vitro refolding (30) . The method for the recombinant expression in E. coli, refolding, and purification of mouse sPLA 2 -IIF will be reported elsewhere.
2 SDS-PAGE demonstrated that recombinant mouse and human sPLA 2 -IIFs exist as a mixture of monomer and homodimer. Reduction by dithiothreitol gave only the monomeric protein, implying that a free cysteine residing in the long Cterminal extension contributes to formation of an intermolecular disulfide-linked homodimer.
2 Anti-mouse and human sPLA 2 -IIF antisera were prepared in rabbits by Cocalico Biologicals Inc., as described previously (23) . Antisera did not cross-react with other sPLA 2 s (sPLA 2 -IB, -IIA, -IIC, -IID, -IIE, -IIF, -V, and -X) when 50 ng quantities of these enzymes were analyzed by immunoblotting.
Establishment of Transfectants-Establishment of HEK293 transformants was performed as described previously (12) (13) (14) (15) (16) . Briefly, 1 g of plasmid (sPLA 2 cDNA subcloned into the pCDNA3.1 vector) was mixed with 2 l of LipofectAMINE PLUS in 100 l of Opti-MEM medium for 30 min and then added to cells that had attained 40 -60% confluence in 12-well plates (Iwaki Glass) containing 0.5 ml of Opti-MEM. After incubation for 6 h, the medium was replaced with 1 ml of fresh culture medium. After overnight culture, the medium was replaced with 1 ml of fresh medium and culture was continued at 37°C in an incubator flushed with 5% CO 2 in humidified air. The cells were cloned by limiting dilution in 96-well plates in culture medium supplemented with 1 mg/ml geneticin. After culture for 3-4 weeks, wells containing a single colony were chosen, and the expression of each protein was assessed by RNA blotting. The established clones were expanded and used for the experiments as described below.
To establish double transformants expressing sPLA 2 -glypican or sPLA 2 -12/15-LOX in combination, cells expressing each sPLA 2 were subjected to a second transfection with glypican cDNA subcloned into pCDNA3.1/Zeo(ϩ) or 12/15-LOX cDNA subcloned into pCDNA3.1/Hyg(ϩ) using LipofectAMINE PLUS. Three days after the transfection, the cells were used for the experiments or seeded into 96-well plates and cloned by culturing in the presence of 50 g/ml zeocin or hygromycin to establish stable transformants.
To assess functional coupling between sPLA 2 -IIF and either of the two COX isozymes, cells stably expressing sPLA 2 -IIF were transfected with COX-1 or COX-2 subcloned into pCDNA3.1 using LipofectAMINE 2000. Three days after the transfection, the cells were activated with A23187 to measure PGE 2 generation and were subjected to immunoblotting to examine COX-1 or COX-2 expression (see below).
RBL-2H3 cells were seeded into 150-mm diameter dishes and cultured for 2ϳ3 days to subconfluency. The cells (10 7 cells) were harvested, washed twice with Opti-MEM, and suspended in 400 l of Opti-MEM. The cells were mixed with each cDNA (2ϳ5 g) and subjected to electroporation (BTX electroporator ECM600, at 200 V pulse amplitude, 900 F capacitance). After culturing for 2 days, the cells were resuspended in 10 ml of culture medium containing 800 g/ml geneticin and seeded into 96-well plates (100 l/well). After culture for 2 weeks, single colonies were expanded into 12-well plates. After reaching confluence, the expression of sPLA 2 was assessed by RNA blotting. As a control, cells transfected with the empty pCDNA3.1 vector were used.
Measurement of sPLA 2 Activity-sPLA 2 activity was assayed by measuring the amounts of free radiolabeled fatty acids released from the substrate 1-palmitoyl-2-
14 C]linoleoyl-PE (2-LA-PE), 2-AA-PC, or 2-LA-PC (Amersham Biosciences). Each reaction mixture (total volume 250 l) consisted of appropriate amounts of the required sample, 100 mM Tris-HCl (pH 7.4), 4 mM CaCl 2 , and 10 M substrate. After incubation for 10 -30 min at 37°C, [ 14 C]AA was extracted, and radioactivity was quantified, as described previously (46) .
Heparin Binding-Affinity of sPLA 2 s for heparin-Sepharose was assessed as described previously (12) . Briefly, ϳ25 ml of culture supernatants of HEK293 transfectants were applied to a heparin-Sepharose column (1 ϫ 5 cm) pre-equilibrated with 10 mM Tris-HCl, pH 7.4, containing 150 mM NaCl (TBS) at a flow rate of 20 ml/h. After extensive washing with TBS, the bound proteins were eluted using 10 mM TrisHCl, pH 7.4, with a 0.15-1 M NaCl gradient. The PLA 2 activities of each fraction was measured as described above.
RNA Blotting-Approximately equal amounts (ϳ5 g) of total RNA obtained from the cells were applied to separate lanes of 1.2% (w/v) formaldehyde-agarose gels, electrophoresed, and transferred to Immobilon-N membranes (Millipore). The resulting blots were then probed with the respective cDNA probes that had been labeled with [ 32 P]dCTP (Amersham Biosciences) by random priming (Takara Biomedicals). All hybridizations were carried out as described previously (12) (13) (14) (15) (16) 46) . Equal loading of RNA in each lane was verified by reprobing the same membranes with glyceraldehyde-3-phoshate dehydrogenase (GAPDH) cDNA (CLONTECH) (not shown).
SDS-PAGE/Immunoblotting-Lysates from 10 5 cells were subjected to SDS-PAGE using 10% gels under a reducing condition. The separated proteins were electroblotted onto nitrocellulose membranes (Schleicher and Schuell) using a semi-dry blotter (MilliBlot-SDE system; Millipore). After blocking with 3% (w/v) skim milk, the membranes were probed with the respective antibodies (1:20,000 dilution for COX-1 and 1:5,000 dilution for COX-2) for 2 h, followed by incubation with horseradish peroxidase-conjugated anti-goat IgG (1:5,000 dilution) for 2 h, and were visualized using the ECL Western blot system (Amersham Biosciences) (12) (13) (14) (15) (16) .
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)-Synthesis of cDNA was performed using 0.5 g of total RNA from mouse tissues and avian myeloblastosis reverse transcriptase, according to the manufacturer's instructions supplied with the RNA PCR kit (Takara Biomedical). Subsequent amplification of the cDNA fragments was performed using 1 l of the reverse-transcribed mixture as a template with mIIF-5Ј primer and mIIF-⌬C primer (see below). The PCR condition was 94°C for 30 s and then 35 cycles of amplification at 94°C for 5 s and 68°C for 4 min, using the Advantage cDNA polymerase mixture (CLONTECH). Expression of GAPDH was assessed by 25 cycles of PCR amplification using specific primers (CLONTECH). The PCR products were analyzed by 1% agarose gel electrophoresis with ethidium bromide. The gels were further subjected to Southern blot hybridization using mouse sPLA 2 -IIF cDNA as a probe.
Construction of sPLA 2 -IIF Mutants-sPLA 2 -IIF mutants were produced by PCR with the Advantage cDNA polymerase mixture. The condition of PCR was 25 cycles at 94°C, 55°C, and 72°C for 30 s each. The primers used were as follows: mIIF-5Ј primer, 5Ј-ATGAAGAAAT-TCTTTGCCATC-3Ј; mIIF-3Ј-primer, CTAGGTTGAGACAGGGGTCGC-3Ј; mIIF-⌬C primer, 5Ј-TTAGCAGTTGGGTGTGGGGCC-3Ј; mIIF-C136S primer, 5Ј-GAAGTCACCTCTGGCATG GC-3Ј; mIIF-C136S AS primer, 5Ј-GCCATGCCCAGAGGTGACTTC-3Ј; hIIF-5Ј primer, 5Ј-AT-GAAGAAGTTCTTCACCGTG-3Ј; hIIF-3Ј primer, 5Ј-CTAGGGAGGGG-CGGGGGGCGC-3Ј; hIIF-⌬C primer, 5Ј-GTAGCAGGTGACCTCCTCA-GG-3Ј; mIIF-FLAG primer, 5Ј-TTACTTGTGATCGTCGTCCTTGTAGT-CGGTTGAGACAGGGGTCGC-3Ј; mIIF-⌬C primer, 5Ј-CTACTTGTGA-TCGTCGTCCTTGTAGTCTTAGCAGTTGGGTGTGG-3Ј; hIIF-FLAG primer, 5Ј-TTACTTGTGATCGTCGTCCTTGTAGTCCTAGGGAGGGG-CGGGGG-3Ј; and hIIF-⌬C-FLAG primer, 5Ј-CTACTTGTGATCGTCG-TCCTTGTAGTCGCTGCAGTTGGGCGTGG-3Ј (FLAG sequence underlined). To prepare the ⌬C mutant constructs, PCR was preformed with mIIF-5Ј and mIIF-⌬C primers or with hIIF-5Ј and hIIF-⌬C primers using species-matched sPLA 2 -IIF cDNA as a template. As for the Cterminal FLAG-tagged constructs, mIIF-5Ј or hIIF-5Ј primer and mIIF-FLAG, mIIF-⌬C-FLAG, hIIF-FLAG, or hIIF-⌬C-FLAG primers were mixed with species-matched sPLA 2 -IIF cDNA and PCR was carried out. To construct the C136S mutant, the first PCR was conducted with mIIF-5Ј and mIIF-C136S AS primers or with mIIF-3Ј and mIIF C136 primers using mouse sPLA 2 -IIF cDNA as a template. The resulting two primary PCR fragments were mixed, denatured at 94°C for 5 min, annealed at 37°C for 30 min and then 55°C for 2 min, and extended at 72°C for 4 min during each cycle. A secondary PCR product with specific mutation was obtained after 25 additional PCR cycles with mIIF-5Ј and mIIF-3Ј primers. Each PCR product was ligated into the pCR3.1 and was transfected into Top10FЈ supercompetent cells (Invitrogen). The plasmids were isolated and sequenced using a Taq cycle sequencing kit (Takara Biomedicals) and an autofluorometric DNA sequencer DSQ-1000L (Shimadzu) to confirm the sequences.
Activation of HEK293 Cells-HEK293 cells (5 ϫ 10 4 /ml) were seeded into each well of 24-or 48-well plates. To assess fatty acid release (12) (13) (14) (15) (16) , [ 3 H]AA or [ 3 H]oleic acid (OA) (both from Amersham Biosciences) (0.1 Ci/ml) was added to the cells in each well on day 3, when they had nearly reached confluence, and culturing was continued for another day. After three washes with fresh medium, 250 l (24-well plate) or 100 l (48-well plate) of RPMI 1640 with or without 10 M A23187 with 1% FCS or 1 ng/ml IL-1␤ and/or 10% FCS was added to each well, and the amount of free [ 3 H]AA or [ 3 H]OA released into the supernatant was measured. The percentage release was calculated using the formula [S/(S ϩ P)] ϫ 100, where S and P are the radioactivity measured in the supernatant and cell pellet, respectively. The supernatants from replicate cells were subjected to the PGE 2 enzyme immunoassay.
To assess transcellular PGE 2 biosynthesis (13), two cell populations (2.5 ϫ 10 4 cells/ml for each) were added to the same wells of 48-well plates and cultured for 4 days. Then the cells were stimulated with IL-1␤ in medium containing 10% FCS for 4 h and PGE 2 released into the supernatants was quantified.
Activation of RBL-2H3 Cells-The cells (5 ϫ 10 4 cells/ml) were seeded into 24-well plates and cultured for 2 days in 1 ml of culture medium. Then the cells were sensitized with 1 g/ml IgE anti-trinitrophenyl in culture medium for 30 min, washed twice with culture medium, and activated for 10 min at 37°C with 10 ng/ml trinitrophenylconjugated bovine serum albumin as an antigen in culture medium (16, 20) . After harvesting the supernatants, the remaining cells were collected and disrupted by two freeze-thawing cycles. Release of LTC 4 was assessed by enzyme immunoassay according to the manufacturer's instruction.
Confocal Laser Microscopy-Cells grown on collagen-coated cover glasses (Iwaki Glass) were fixed with 3% paraformaldehyde for 30 min in phosphate-buffered saline (PBS). After three washes with PBS, the fixed cells were sequentially treated with 1% (w/v) bovine serum albumin (for blocking) and 0.2% (v/v) Triton X-100 (for permeabilization) in PBS for 1 h, with anti-FLAG antibody (1:500 dilution) for 1 h in PBS containing 1% bovine serum albumin, and then with fluorescein isothiocyanate-goat anti-mouse IgG (1:500 dilution) for 1 h in PBS containing 1% bovine serum albumin. After six washes with PBS, the cells were mounted on glass slides using Perma Fluor (Japan Tanner), and the sPLA 2 signal was visualized using a laser scanning confocal microscope (IX70; Olympus), as described previously (14) .
LPS Treatment of Mice-LPS (5 mg/kg) was administered intraperitoneally to 4-week-old male C57BL/6 mice (Nippon Bio-Supply Center). After 24 h, mice were sacrificed by bleeding, their organs were removed, and RNA was extracted by homogenization in TRIzol reagent by 10 strokes of a Potter homogenizer at 1,000 rpm.
Mouse Ear Atopic Dermatitis-Five repeated topical applications of 2,4-dinitrobenzene (DNFB) to the ears of BALB/c, but not C57BL/6, mice result in contact hypersensitivity of the ears and significant elevation of serum IgE level, accompanied by increased T H1 response for the onset of skin dermatitis and T H2 response in the lymph node (53) . Briefly, mouse ears were painted with 25 l of 0.15% (w/v) DNFB or vehicle (acetone:olive oil 3:1) once a week. The ears were removed 24 h after the fifth painting and subjected to RNA extraction. Replicate ear sections were fixed by formalin, embedded in paraffin, and stained with hematoxylin and eosin to verify the progress of inflammation. All the procedures and analyses of other parameters are detailed elsewhere (53) .
Immunohistochemistry-The fresh synovial tissues of human rheumatoid arthritis were obtained at synovectomy, and promptly placed in optimal cutting temperature compound (Sakura Industry), frozen, and then stored at Ϫ80°C for 1 week. Thin sections (4 m thickness) from the frozen tissues were fixed in acetone for 10 min and dried in air for 10 min. The samples were pretreated with 0.3% (v/v) H 2 O 2 for 5 min in TBS and then with 5% (w/v) skim milk in TBS containing 0.02% (v/v) Tween 20. After washing with TBS containing 0.02% Tween 20 three times, they were sequentially incubated for 30 min with anti-human sPLA 2 -IIF antiserum for 10 min with biotinylated anti-mouse immunoglobulin, and for 10 min with peroxidase-conjugated streptavidin at room temperature. After washing, the sections were visualized with diaminobentidine tetrahydrochloride. Biotinylated anti-mouse immunoglobulin, peroxidase-conjugated streptavidin and diaminobentidine tetrahydrochloride were supplied in the LSAB kit (Dako).
Statistical Analysis-Data were analyzed by Student's t test. Results are expressed as the mean ϩ S.E., with p ϭ 0.05 as the limit of significance.
RESULTS
Enzymatic Properties-cDNAs for wild-type (WT) mouse or human sPLA 2 -IIF, a mutant in which the unique portion of the C-terminal extension was entirely deleted (⌬C), and another mutant in which the extra Cys residue in the long C-terminal extension that likely allows formation of a disulfide-linked homodimer was replaced by Ser (C136S), the structures of which are illustrated in Fig. 1A , were each transfected into HEK293 cells. After selection with geneticin, clones stably expressing WT and mutant enzymes at comparable levels, as assessed by RNA blotting (Fig. 1B) , were used in subsequent studies. Since results with mouse and human enzymes turned out to be similar, we hereafter report the results mostly with the mouse enzyme.
When the in vitro enzymatic properties of the WT and mutant sPLA 2 -IIF were examined using culture supernatants of the transfectants as enzyme sources, the activity of the ⌬C mutant toward 2-AA-PE was slightly lower than, whereas the activity of the C136S mutant was comparable with, that of the WT enzyme (Fig. 1C) . The WT enzyme (Fig. 1D ) and both mutants (data not shown) hydrolyzed PE ϳ8 times more efficiently than PC, with only a modest preference for AA to linoelic acid at the sn-2 position. In comparison, the PE versus PC hydrolytic ratios of human sPLA 2 -IIA, -V, and -X were approximately Ͼ100:1, 2:1, and 1:1, respectively, under the same assay condition (12) (13) (14) (15) . The WT and mutant enzymes showed a similar Ca 2ϩ dependence with an optimal pH at 7-9 (data not shown). Studies with highly pure preparations of WT and the ⌬C mutant of sPLA 2 -IIF, produced as recombinant proteins in E. coli, showed that both proteins had comparable activity on 1-palmitoyl-2-oleoyl-phosphatidylserine vesicles or 1-palmitoyl-2-oleoyl-phosphatidylglycerol (less than 1.3-fold difference) vesicles. 2 These data are consistent with our current studies using HEK293 cell transfectants showing that both the WT enzyme and the ⌬C mutant have similar specific activities on phospholipid vesicles in vitro. Fig. 2A) . IL-1-stimulated [ 3 H]AA release by the sPLA 2 -IIF-expressing cells proceeded gradually over 8 h of culture (data not shown), with a concomitant increase in PGE 2 generation over the same time period (Fig. 2B) .
IL-1-stimulated PGE 2 generation by the sPLA 2 -IIF-expressing cells was completely blocked by the COX-2 inhibitor NS-398 (see below), indicating absolute dependence of this delayed PGE 2 generation on endogenous COX-2. The sPLA 2 -IIF-expressing cells expressed more COX-2 ( Fig. 2C) and its downstream mPGES (Fig. 2D ) than did the control cells after IL-1 stimulation. The expression of COX-2 peaked at 1 h and then declined gradually (Fig. 2C) , whereas that of mPGES, which was already visible even before IL-1 stimulation, increased to reach a maximum by 1 h and maintained a plateau level thereafter (Fig. 2D) , in the sPLA 2 -IIF-expressing cells. The enhanced expression of COX-2 (14 -16) and mPGES (Fig. 2D ) was also observed with the cells transfected human sPLA 2 -V as well as those transfected with other group II subfamily sPLA 2 s, such as sPLA 2 -IIA and -IID, but not those transfected with sPLA 2 -X (data not shown). When HEK293 cells transfected with sPLA 2 -IIF were co-cultured with those transfected with COX-2 (the transcellular PG biosynthesis assay (13)), PGE 2 production was severalfold higher than that produced by the sPLA 2 -IIF or COX-2 single transfectants (Fig. 2E) , indicating that sPLA 2 -IIF secreted from one cell can act on neighboring COX-2-expressing cells. Furthermore, PGE 2 generation by the COX-2/mPGES co-transfectants was further augmented when co-cultured with the sPLA 2 -IIF-expressing cells (Fig. 2E) . sPLA 2 -IIF is thus capable of supplying AA to the downstream sequential biosynthetic enzymes, COX-2 and mPGES, for delayed PGE 2 production in autocrine and paracrine fashions.
A23187-induced immediate AA release (0 -30 min) was also markedly increased in the sPLA 2 -IIF-expressing cells over the control cells (Fig. 2F) . When either COX-1 or COX-2 was cotransfected with sPLA 2 -IIF (the expression of each COX, as assessed by Western blotting, is shown in Fig. 2G, bottom) , A23187-induced immediate PGE 2 production via each COX was markedly augmented in the sPLA 2 -IIF-expressing cells relative to replicate control cells (Fig. 2G) .
The truncated sPLA 2 -IIF mutant ⌬C increased A23187-induced immediate AA release and IL-1-induced delayed AA release and PGE 2 generation only modestly, whereas the mutant C136S was as active as WT in both immediate and delayed responses (Fig. 3, A-C) . A catalytically inactive sPLA 2 -IIF mutant, G29S, in which Gly 29 in the conserved Ca 2ϩ -binding site was replaced by Ser, was unable to elicit AA release under all conditions tested (data not shown). When WT and ⌬C mutant sPLA 2 -IIF enzymes were transfected into rat mastocytoma RBL-2H3 cells (the expression of WT and mutant ⌬C was verified by Northern blotting (Fig. 3D,  inset) ), the WT enzyme increased IgE/antigen-dependent immediate production of LTC 4 markedly over the replicate mocktransfected cells, whereas LTC 4 production by the ⌬C-transfected cells was minimal (Fig. 3D) . Given the fact that the ⌬C mutant has PLA 2 activity nearly comparable with that of the WT enzyme in vitro (Fig. 1C) , these observations suggest that the C-terminal extension unique to sPLA 2 -IIF may be crucial for its cellular function.
Cellular Actions of sPLA 2 -IIF Occur Independently of HSPG-More than 95% of the expressed sPLA 2 -IIF was secreted from the HEK293 transfectants into the culture medium, and washing the cells with 1 M NaCl, which solubilizes the HSPG-associated form of several group II subfamily sPLA 2 s from cell surfaces (12-16), did not alter the recovery of sPLA 2 -IIF. This result suggests that sPLA 2 -IIF has a very weak or no affinity for heparanoids. To confirm this, we tested the binding of this enzyme to heparin-Sepharose. When the pooled culture supernatant of the sPLA 2 -IIF-expressing cells was applied to the heparin-Sepharose column, the activity of sPLA 2 -IIF was recovered exclusively in the flow-through fraction (Fig. 4A, top) . In comparison, sPLA 2 -IID, used as an example of a heparin-binding sPLA 2 , bound tightly to the column (Fig. 4A, middle) and nearly 40% of the enzyme expressed in HEK293 cells was recovered only after cells were washed with 1 M NaCl (16). The sPLA 2 -IIF mutant C136S also failed to bind to the heparin-Sepharose column (data not shown), whereas the truncated mutant ⌬C showed a weak heparanoid affinity, with as much as 10% being associated with the column (Fig.  4A, bottom) . This increase in heparin affinity of the ⌬C mutant is likely because the extra C-terminal extension, which is rich in acidic amino acids (28, 30) , is absent.
Consistent with the heparin-nonbinding feature, the AAreleasing function of sPLA 2 -IIF was not affected by coexpression with the HSPG glypican (Fig. 4B) , which acts as a functional adaptor for the heparin-binding group II subfamily sPLA 2 s (IIA, IID, and V) (14, 16) . Indeed, under the same experimental condition, AA release by sPLA 2 -IIA, the function of which largely depends on HSPG, was significantly augmented, whereas that by sPLA 2 -X, which utilizes the HSPGindependent pathway, was unaffected, by glypican coexpression (Fig. 4B) , as reported previously (14, 16) . Furthermore, IL-1-stimulated AA release and PGE 2 generation by sPLA 2 -IIF was insensitive to exogenous heparin (Fig. 4C) . Under the same condition, AA and PGE 2 release by sPLA 2 -IIA was markedly suppressed (due to transfer of the cell surface-bound sPLA 2 -IIA to soluble heparin (14, 16) ), whereas AA release by sPLA 2 -X was insensitive to exogenous heparin (Fig. 4C) . These results imply that sPLA 2 -IIF acts on cells in a cellular HSPG-independent manner.
To determine the cellular sites of sPLA 2 -IIF action, we performed immunocytostaining of HEK293 cells transfected with mouse and human sPLA 2 -IIFs that were C-terminal tagged with the FLAG epitope. Their expression levels were verified by Northern blotting and enzyme activity (data not shown). Confocal laser microscopic analyses revealed that the outline of the cells was intensely stained for human (Fig. 5A) and mouse (Fig.  5B ) sPLA 2 -IIFs, indicating their location on the plasma membrane. There were no detectable cytoplasmic punctate and perinuclear signals, which were prominent when the other group II subfamily sPLA 2 s utilizing the HSPG-shuttling pathway, such as sPLA 2 -IIA, IID, and V, were immunostained (14, 16). Washing the cells with heparin did not affect the plasma membrane staining of sPLA 2 -IIF (data not shown). In contrast, the plasma membrane signal for the truncated mutant ⌬C was very faint (Fig. 5C) .
sPLA 2 
-IIF Action Is Facilitated by 12/15-LOX Metabolites-
The fact that the cellular AA releasing functions of sPLA 2 -IIF ( Fig. 2A) as well as the other group II subfamily sPLA 2 s (IIA, IID, and V) (12) (13) (14) (15) (16) are markedly augmented by appropriate stimuli (IL-1 and A23187 in this case) argues that their phospholipid-hydrolytic actions are, in common, facilitated by cellular membrane rearrangement that occurs during cell activation. Since lipid oxidation is one of the key events leading to membrane rearrangement (10, 44, 45) and since the increased AA release by sPLA 2 -IIA or sPLA 2 -V transfectants is attenuated by treatment with several antioxidants that inhibit 12/15-LOX (10), we examined the effect of NDGA, a 12/15-LOXinhibitable antioxidant (10), on the AA-releasing function of sPLA 2 -IIF. As illustrated in Fig. 6A, IL-1-stimulated [ 3 H]AA release and PGE 2 generation by HEK293 cells expressing sPLA 2 -IIF and sPLA 2 -IIA, as well as those expressing sPLA 2 -V and sPLA 2 -IID (data not shown), were markedly reduced by NDGA. Analysis by thin layer chromatography confirmed that the released radioactivity was largely (Ͼ90%) associated with AA (data not shown), indicating that the suppression by NGDA was not due to the inhibition of the release of LOX products. In contrast, AA release by sPLA 2 -X-expressing cells was largely NDGA-insensitive (Fig. 6A) , consistent with the notion that this enzyme does not require membrane rearrangement for its cellular action (15, 16, (37) (38) (39) (40) . Furthermore, AA release by sPLA 2 -IIF, like that by sPLA 2 -IIA (10), was markedly augmented following 12/15-LOX co-transfection (Fig. 6B) . The COX-2 inhibitor NS-398, which almost completely blunted PGE 2 generation, did not alter AA release by these sPLA 2 s (Fig. 6A) . Collectively, these results suggest that certain 12/15-LOX, but not COX, reaction products may facilitate membrane rearrangement and result- ant AA releasing function of the group II subfamily sPLA 2 s.
Induction of sPLA 2 -IIF during Inflammation-C57BL/6 mice were injected with LPS intraperitoneally, and the expression of sPLA 2 -IIF in several tissues before and 24 h after the injection was examined by RT-PCR, followed by Southern blotting. Although the basal expression level of sPLA 2 -IIF was undetectable or barely detectable in the tissues examined (brain, heart, liver, colon, and testis), it was markedly increased in these tissues after LPS treatment (Fig. 7A) .
The expression of sPLA 2 -IIF in mouse ears with or without five repeated treatments with DNFB, which induces a chronic inflammation similar to human atopic dermatitis (53), was next examined by RT-PCR/Southern blotting. In the ears of BALB/c mice, which represent a hypersensitive strain displaying profound T H1 and T H2 responses in this atopic dermatitis model (53) , there was a marked elevation in the expression of sPLA 2 -IIF after DNFB challenge (Fig. 7B) . In contrast, its expression was unchanged in the DNFB-treated ears of C57BL/6 mice (Fig. 7B), a low responder strain (53) .
Finally, we performed immunohistochemical staining of human rheumatoid arthritic tissues using a polyclonal antisPLA 2 -IIF antiserum. Intense enzyme staining was seen in capillary endothelial cells (Fig. 8, A and B) , synovial lining cells (Fig. 8, A and C) , synovial sublining cells (Fig. 8, A and  D) , and plasma cells (i.e. larger cells) (Fig. 8, B-D) in the intima. Some lymphocytes were also weakly positive, whose cytosol was scant (Fig. 8B) . Control antiserum did not stain these tissue sections at all (data not shown). Identification of the above cell variety was judged from conventional hematoxylin and eosin staining serially sectioned to the specimen used for immunohistochemistry. DISCUSSION Current evidence suggests that the cellular AA releasing function of various sPLA 2 s is crucially influenced by their ability to bind to the PC-rich lipid interface for some enzymes (15,  16, 33-35, 37-40, 47 ) and to anionic heparanoids for others (12-16, 46) . sPLA 2 -V and -X, which bind well to PC-rich vesi- cles in vitro (35, 37) , are capable of binding to the PC-rich outer leaflet of the plasma membrane of unstimulated cells leading to the release of AA and OA (15, 16, 33-35, 37-40, 47) . The AA released by these sPLA 2 s may pass across the plasma membrane, diffuse into the cytosol (or possibly with an aid of fatty acid-binding proteins), and reach the perinuclear COX and 5-LOX enzymes for eicosanoid synthesis (transcellular AA movement is also possible). The heparin binding, basic enzymes sPLA 2 -IIA, -IID, and -V bind to the HSPG glypican and are sorted into caveolin-rich vesicular and perinuclear compartments in activated cells (12) (13) (14) (15) (16) 46) . This localization may spatially and temporally allow efficient transfer of AA to adjacent COX and 5-LOX enzymes. Membrane rearrangement that may occur during cell activation is also a prerequisite event for the function of the HSPG-shuttled sPLA 2 s, where exposure of anionic and/or oxidative phospholipids may facilitate their interfacial membrane association and subsequent hydrolysis (10, 12-16, 44 -46) . Moreover, this perturbed membrane microdomain appears to be rich in AA relative to other fatty acids, since these sPLA 2 s release AA in preference to OA (12, 15) despite the fact that they display almost no fatty acyl selectivity in vitro (6, 7, 12, 26, 27, 31, 35) . This pathway is supported by a recent study by Cho and co-workers (54), who demonstrated the HSPG-and catalytic activity-dependent internalization of and subsequent substrate hydrolysis at the perinuclear membrane by exogenously added sPLA 2 -V and sPLA 2 -IIA (in the latter case, cell membrane perturbation by cytokine priming is essential).
The present functional analyses of sPLA 2 -IIF reveal that this enzyme behaves in a manner similar, but not identical, to other group II subfamily sPLA 2 s. In the HEK293 cell system, sPLA 2 -IIF releases AA in preference to OA in response to IL-1 and augments IL-1-stimulated COX-2 expression and attendant PGE 2 production (Fig. 2, A-D) . The expression of mPGES, a terminal enzyme acting downstream of COX-2 in the delayed PGE 2 -biosynthetic pathway (52) , is also augmented by sPLA 2 -IIF and by other group II subfamily sPLA 2 s (Fig. 2D) , implying that the increased AA release and the up-regulation of the two sequential downstream enzymes (COX-2 and mPGES) contribute to the amplification of the PGE 2 -biosynthetic cascade. Although the mechanisms for the induction of COX-2 and mPGES by the group II subfamily sPLA 2 s are unclear, requirement of their catalytic activities for this event (15) suggests that certain reaction products spatiotemporally generated by the sPLA 2 action in compartmentalized sites may in turn trigger the COX-2/mPGES induction machinery. sPLA 2 -IIF also elicits A23187-induced immediate AA release and, if COX-1 is expressed by transfection, can be coupled with COX-1 for immediate PGE 2 synthesis (Fig. 2, F and G) . Furthermore, AA release by sPLA 2 -IIF is attenuated by the LOX-inhibitable antioxidant NDGA and, conversely, facilitated by introduction of the membrane-oxidizing enzyme 12/15-LOX (Fig. 6) . All of these aspects are commonly observed with the signaling group II subfamily sPLA 2 s such as IIA, IID, and V (10).
However, unlike these heparin-binding group II subfamily sPLA 2 s, sPLA 2 -IIF does not bind to heparanoids, and its function does not depend on the HSPG glypican (Fig. 4) . The heparin-nonbinding feature of sPLA 2 -IIF is consistent with the fact that this enzyme is an acidic protein (calculated pI of 5.4 and 4.7 for the mouse and human enzymes, respectively), whereas other group II subfamily sPLA 2 s are basic (1, 2, (25) (26) (27) (28) (29) (30) . Likely due to its failure to bind cellular HSPG, sPLA 2 -IIF is largely secreted into the extracellular medium. Of interest, an immunocytochemical study demonstrates that at least some sPLA 2 -IIF remains associated with the plasma membrane (Fig.  5) , rather than in the vesicular and perinuclear components in which the heparin-binding sPLA 2 s are commonly distributed (10, 14, 16) . Thus, sPLA 2 -IIF is the first example among the "group II" sPLA 2 s that is capable of functioning on the plasma membrane with no interaction with HSPG.
As noted above, the plasma membrane action of sPLA 2 -X and -V depends essentially on their high capacity to interact with PC-rich membranes (16, 35, (37) (38) (39) (40) 47) . Studies of the action of sPLA 2 -IIF on phospholipid vesicles in vitro shows that it hydrolyzes PE ϳ8 times more efficiently than PC (Fig. 1D ), yet this PC hydrolyzing activity is still far more efficient than that of sPLA 2 -IIA (30). Mouse and human sPLA 2 -IIFs bind to PC vesicles in vitro with affinities comparable with those of sPLA 2 -V and -X. 2 Modest and parallel increases in AA and OA release by sPLA 2 -IIF-expressing HEK293 cells cultured in 10% FCS ( Fig. 2A) is compatible with marked increases in AA and OA release in sPLA 2 -X-expressing cells (15) and suggests that sPLA 2 -IIF, like sPLA 2 -X, acts on the plasma membrane. Interaction with PC in the plasma membrane is also supported by the finding that sPLA 2 -IIF, which is exocytosed rapidly from RBL-2H3 cells by degranulation, elicits LTC 4 production (Fig.  3D) , an event occurring predominantly through the external plasma membrane pathway (16) . However, it is also possible that sPLA 2 -IIF releases AA from IgE/Ag-stimulated RBL-2H3 cells by acting on perturbed membrane microdomain on the surface, as discussed below.
Despite these facts, the ability of sPLA 2 -IIF to bind PC in the outer plasma membrane appears insufficient for optimal action of this enzyme, since unlike sPLA 2 -X that can elicit the full AA-releasing response without an additional stimulation (15, 16, (37) (38) (39) (40) , sPLA 2 -IIF requires an appropriate stimulus, such as IL-1, to do so ( Fig. 2A) . Thus, it is tempting to speculate that cell activation signaling may lead to formation of a perturbed microdomain on the plasma membrane, to which sPLA 2 -IIF preferentially attacks. This putative microdomain for sPLA 2 -IIF action may contain anionic and oxidized phospholipids, and also be enriched in AA-containing phospholipids because the IL-1-stimulated response is AA-selective ( Fig. 2A) .
Site-directed mutagenesis of sPLA 2 -IIF in two cell models (i.e. HEK293 and RBL-2H3) shows that the unique C-terminal extension is essential for its cellular function (Fig. 3) , even though the truncation of this region does not profoundly affect the in vitro enzyme activity (Fig. 1C) . It may be noted that the plasma membrane staining, which appears with the WT en- zyme, is not observed if this C-terminal domain is deleted (Fig.  5) . The plasma membrane-acting enzyme, sPLA 2 -X, does not give a clear cell outline staining (16) , probably because the dissociation constant for sPLA 2 -X on PC-rich vesicles in vitro is ϳ100 M (i.e. 50% of sPLA 2 -X is vesicle-bound in the presence of 100 M PC), 2 and the plasma membrane phospholipid concentration in these cellular studies is estimated to be Ͻ10 M. These results raise the intriguing possibility that the unique C-terminal extension is required for this enzyme to tightly interact with the plasma membrane. The mutation of a free cysteine residing in the middle portion of this domain does not alter the in vitro or cellular functions of the enzyme (Figs. 1C  and 3 ), indicating that homodimer formation or possible heterodimer formation with other cellular proteins via this cysteine residue is nonessential. Another notable characteristics of this extra C-terminal extension is the abundance of acidic and proline residues (28, 30) . However, it is currently unclear whether this unique feature is responsible for the plasma membrane distribution of the enzyme.
Taken together, we prefer the model in which sPLA 2 -IIF can act on the plasma membrane through a combined interaction of its interfacial binding surface (that which surrounds the opening of the catalytic site slot) and the C-terminal extension. Cell activation-directed transbilayer movement of anionic phospholipids and accelerated oxidation may further increase its ability to interact with the plasma membrane and thereby increase AA release. However, the possibility that a small, undetectable, fraction of enzyme is present in internalized perinuclear compartments, localized through an unknown pathway, cannot be ruled out. Regardless of the mechanisms involved, our present results clearly indicate that sPLA 2 -IIF is an additional member of the signaling PLA 2 s that can control cellular AA metabolism.
As are other group II subfamily sPLA 2 s (6-11, 27, 29, 32), sPLA 2 -IIF is a stimulus-inducible enzyme, whose expression is markedly induced in various tissues during at least some forms of inflammation (Figs. 7 and 8) . The presence of potential binding motifs for several stimulus-activated transcription factors, such as C/EBP, CREB, NFB, and AP-1, within ϳ2.5 kb upstream of the human sPLA 2 -IIF gene, as revealed by nucleic data base search, also supports this notion. Although high level sPLA 2 -IIF expression has been reported in the adult mouse testis (28) , in this study its expression in this tissue is low (Fig.  7A) , probably due to differences in mouse strains or ages. Our present data indicate that its expression is induced (even though at lower expression levels than sPLA 2 -V (32)) in a variety of tissues after LPS challenge (Fig. 7A) . Increased expression of sPLA 2 -IIF in the atopic dermatitic ears of mice (Fig.  7B) , together with the fact that it is expressed in murine cultured mast cells (20) and that it increases LTC 4 production in a rat mast cell line (Fig. 3D) , argues that this enzyme may be involved in exacerbation of the allergic response.
sPLA 2 -IIF is also detected in human rheumatoid arthritic tissues, in which synovial lining cells in the intima, capillary endothelial cells, and plasma cells are intensely stained (Fig.  8) . Previous work has shown that sPLA 2 -IIA is abundantly present in rheumatoid arthritic tissues (6 -8, 43 ), yet the presence of other related sPLA 2 enzymes have not been addressed. An immunohistochemical study has demonstrated that sPLA 2 -IIA exists in fibroblastic and macrophage-like cells in the synovial lining and subsynovial lining layers, perineural cells, endothelial cells, mast cells, vascular smooth muscle cells, and extracellular matrices (43) , observations that are largely consistent with our own immunohistochemical study. 3 Furthermore, our preliminary analyzes using the sPLA 2 group-specific antisera show that other sPLA 2 s, particularly those belonging to the group II subfamily, are also present in rheumatoid arthritic tissues. 3 Co-distribution of related sPLA 2 s in rheumatoid synovial epithelium is suggestive of their redundant functions in AA release, whereas sPLA 2 -IIF expressed in the plasma cells, in which other sPLA 2 s were not detected, 3 might play a unique immunoregulatory role.
Even though sPLA 2 -IIF is capable of augmenting AA metabolism in the HEK293 and RBL-2H3 cell overexpression system and is induced during inflammation, there is still no direct evidence that this enzyme indeed plays a role in lipid mediator production under pathophysiological conditions in vivo. There may be some novel functions of sPLA 2 s other than the regulation of AA metabolism. For instance, sPLA 2 -IIA has a bactericidal activity, which may be a major physiological function of this isozyme (22) (23) (24) . It is unlikely that sPLA 2 -IIF plays a similar anti-bacterial role, since this enzyme is rather acidic (28, 30) , whereas cationic property is a prerequisite for the anti-bacterial function of sPLA 2 s (22) (23) (24) . Several sPLA 2 several cellular functions through binding to the sPLA 2 receptor, an action that occurs independently of the catalytic activity (49, 50) , although it is currently unknown whether sPLA 2 -IIF binds to the receptor. The high expression of sPLA 2 -IIF in embryonic tissues and testis (28, 30) may reflect a unique functional role for this enzyme. The presence of multiple sPLA 2 enzymes in local environments forces us to explore the precise functions of each enzyme in more detail. This should be of great value for the development of novel sPLA 2 inhibitors as drugs with a broad or specific spectrum of therapeutic and prophylactic activities.
